Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-09-01 16:39:35 ET · period of report 2026-08-28 · accession 0000875320-26-000267 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-01 16:39 | 2026-08-28 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +5,000 | 11.6K | +75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-28 | A | A | 5,000 | $0.00 | 11,624 | D | — | — | (F1) Restricted stock unit award that vests on 03/01/2029. |